Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)

Short Term ◽

Primary Progressive ◽

Term Data

A Preliminary Study Comparing the Sensitivity of Serial Monthly Enhanced MRI After Standard and Triple Dose Gadolinium-DTPA for Monitoring Disease Activity in Primary Progressive Multiple Sclerosis

Journal of Neuroimaging ◽

10.1111/jon19988288 ◽

1998 ◽

Vol 8 (2) ◽

pp. 88-93 ◽

Cited By ~ 11

Author(s):

M. Filippi ◽

M. Rovaris ◽

C. Gasperini ◽

R. Capra ◽

S. Bastianello ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Gadolinium Dtpa ◽

Primary Progressive ◽

Enhanced Mri ◽

Preliminary Study ◽

Triple Dose

Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany

Clinical Neurology and Neurosurgery ◽

10.1016/j.clineuro.2020.106142 ◽

2020 ◽

Vol 197 ◽

pp. 106142 ◽

Cited By ~ 1

Author(s):

Sebastian Rauer ◽

Muna-Miriam Hoshi ◽

Refik Pul ◽

Mathias Wahl ◽

Matthias Schwab ◽

...

Keyword(s):

Multiple Sclerosis ◽

Compassionate Use ◽

Short Term ◽

Disease activity impacts disability progression in primary progressive multiple sclerosis

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2019.101892 ◽

2020 ◽

Vol 39 ◽

pp. 101892 ◽

Cited By ~ 1

Author(s):

M. Marrodan ◽

C. Bensi ◽

A. Pappolla ◽

J.I. Rojas ◽

M.I. Gaitán ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Disability Progression ◽

Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy

Journal of Neurology ◽

10.1007/pl00007860 ◽

2002 ◽

Vol 249 (2) ◽

pp. 171-177 ◽

Cited By ~ 21

Author(s):

Valerie L. Stevenson ◽

Stephen M. Smith ◽

Paul M. Matthews ◽

David H. Miller ◽

Alan J. Thompson

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Cerebral Atrophy ◽

Searching for early CSF biomarkers of primary progressive multiple sclerosis

10.26226/morressier.5b719e465aff74008ae4cb58 ◽

2018 ◽

Author(s):

Damiano Marastoni ◽

Roberta Magliozzi

Keyword(s):

Multiple Sclerosis ◽

Csf Biomarkers ◽

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Case Medical Research ◽

10.31525/ct1-nct04035005 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Faculty Opinions recommendation of Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955622.793460622 ◽

2012 ◽

Author(s):

Monica Marta

Keyword(s):

Multiple Sclerosis ◽

Primary Progressive ◽

Meningeal Inflammation

Faculty Opinions recommendation of Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718018944.793478763 ◽

2013 ◽

Author(s):

Marco Rovaris

Keyword(s):

Multiple Sclerosis ◽

Disease Course ◽

Gray Matter Atrophy in the Cortico-Striatal-Thalamic Network and Sensorimotor Network in Relapsing–Remitting and Primary Progressive Multiple Sclerosis

Neuropsychology Review ◽

10.1007/s11065-021-09479-3 ◽

2021 ◽

Author(s):

Yuan Cao ◽

Wei Diao ◽

Fangfang Tian ◽

Feifei Zhang ◽

Laichang He ◽

...

Keyword(s):

Multiple Sclerosis ◽

Gray Matter ◽

Sensorimotor Network ◽

Primary Progressive ◽

Gray Matter Atrophy ◽

Relapsing Remitting

Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression

Journal of Medical Economics ◽

10.1080/13696998.2021.1872585 ◽

2021 ◽

Vol 24 (1) ◽

pp. 140-149

Author(s):

Laurie J. Brown ◽

Jinjing Li ◽

Matthias Brunner ◽

Martin Snoke ◽

Hai A. La

Keyword(s):

Multiple Sclerosis ◽

Economic Impact ◽

Disease Progression ◽

Societal Costs ◽

Primary Progressive ◽

Delay Disease Progression ◽

Disease Modifying ◽

Disease Modifying Treatment